Search Results - "Miralles, L. S."

How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain by Castañeda, A., Gorostegui, M., Miralles, S.L., Chamizo, A., Patiño, S.C., Flores, M.A., Garraus, M., Lazaro, J.J., Santa-Maria, V., Varo, A., Muñoz, J.P., Mora, J.

“…Naxitamab [humanized 3f8 (hu3F8)] is a humanized monoclonal antibody (mAb) targeting the disialoganglioside GD2. It was approved in 2020 by the United States…”
Get full text

Corrigendum to “How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain”: [ESMO Open, 7 (2022) 100462] by Castañeda, A., Gorostegui, M., Miralles, S.L., Chamizo, A., Patiño, S.C., Flores, M.A., Garraus, M., Lazaro, J.J., Santa-Maria, V., Varo, A., Muñoz, J.P., Mora, J.

Get full text